Hi there,

I suppose you could, but I would ask what the goal would be? The evidence that PO4 is problematic is more-so for chronic burden, and even that is in my is debatable. My thoughts on this here:

http://ukidney.com/news/entry/dream-rct-a-placebo-controlled-trial-of-hyperphosphatemia-management

I would be more considered about other aspects of the AKI than the short term, and theoretical impact of hyperphsphatemia. Furthermore, PO4 binding would not lower PO4 levels quickly and would have little role in a patient who is not eating much (i.e. those with AKI)

Dr. Jordan Weinstein